Description

Pyramax Tablets — Proven Pyramax Tablets Malaria Treatment by Shin Poong Pharmaceutical

When malaria strikes, every hour matters. Pyramax tablets malaria treatment delivers a clinically validated, WHO-prequalified artemisinin-based combination therapy (ACT) designed to clear malaria parasites rapidly and reliably. Manufactured by Shin Poong Pharmaceutical Co. Ltd. of the Republic of Korea — a pharmaceutical leader with nearly five decades of expertise — Pyramax tablets are trusted by healthcare professionals across more than 25 malaria-endemic countries worldwide.

Whether you are a clinician seeking a dependable first-line antimalarial or a patient who needs swift, effective care, Faaiz Pharmacy is proud to stock Pyramax tablets for uncomplicated malaria treatment for adults and children alike.

 

What Are Pyramax Tablets?

Pyramax tablets Shin Poong are a fixed-dose combination antimalarial containing two powerful active substances: pyronaridine tetraphosphate (180 mg) and artesunate (60 mg) per tablet. This combination — commonly referred to as artesunate pyronaridine tablets — brings together a fast-acting artemisinin derivative and a long-acting blood schizonticide into one convenient, once-daily oral tablet.

The result is a dual-action therapy that attacks the malaria parasite at multiple points in its life cycle, significantly reducing the risk of treatment failure and minimising the likelihood of resistance development.

 

Indications: What Does Pyramax Treat?

Pyramax tablets for uncomplicated malaria treatment are indicated for the treatment of acute, uncomplicated malaria caused by:

• Plasmodium falciparum — the most dangerous and drug-resistant malaria species
• Plasmodium vivax — the most geographically widespread malaria parasite

Notably, Pyramax is the only ACT to receive regulatory approval specifically indicated for the blood-stage treatment of both dominant strains of malaria. This dual-strain coverage makes it an exceptionally versatile and valuable antimalarial in any clinical setting.

Pyramax 180 mg/60 mg tablets are suitable for adults and children weighing 20 kg or more. A separate granule formulation is available for infants and young children between 5 kg and under 20 kg.

 

Pyramax 180 mg/60 mg Tablet Dosage Guide

The Pyramax 180 mg/60 mg tablet dosage is administered once daily for three consecutive days, with dosing determined by the patient’s body weight:

Body Weight	Daily Dose
20–24 kg	1 tablet once daily
25–44 kg	2 tablets once daily
45–64 kg	3 tablets once daily
≥ 65 kg	4 tablets once daily

Tablets may be taken with or without food, making adherence easier in diverse clinical environments. If the patient vomits within 30 minutes of the first dose, a repeat dose should be administered. Always follow your prescribing physician’s instructions and refer to the official Summary of Product Characteristics (SmPC) for full dosing guidance.

 

How Pyramax Works: Dual Mechanism of Action

The therapeutic power of artesunate pyronaridine tablets lies in the complementary mechanisms of its two active components:

Artesunate is a water-soluble derivative of artemisinin, the cornerstone of modern malaria treatment. It acts rapidly against multiple stages of the malaria parasite — particularly the early ring-form stage — depleting parasites from the bloodstream within one to two days of treatment initiation.

Pyronaridine tetraphosphate is a long-acting antimalarial that works by blocking a critical metabolic step the parasite needs to survive inside the patient’s red blood cells. Crucially, pyronaridine retains potent activity against chloroquine-resistant strains of both P. falciparum and P. vivax, making it a robust partner in resistant or high-burden settings.

Together, these two agents deliver rapid parasite clearance and sustained post-treatment suppression — the hallmarks of a high-performance ACT.

 

Clinical Evidence: Why Pyramax Tablets Are Trusted

The clinical pedigree behind Pyramax tablets Shin Poong is exceptional. The product was co-developed by Shin Poong Pharmaceutical and Medicines for Malaria Venture (MMV) through more than two decades of rigorous research and development.

Key clinical highlights include:

• Over 12,200 patients evaluated for safety in clinical trials across Africa and Asia
• 95–98% parasite clearance at Day 42 in pivotal Phase III trials, comparable to leading WHO-recommended ACTs
• Parasite clearance within one to two days of initiating treatment
• Real-world effectiveness confirmed in the landmark CANTAM study — the largest real-life Pyramax study to date — spanning over 8,500 malaria episodes across five African countries, with a Day-28 PCR-adjusted cure rate of 98.6%
• Safe for repeat treatments, with efficacy and tolerability maintained even when re-administered up to eight times in a single patient over a two-year follow-up

These results firmly establish Pyramax as a powerful, well-tolerated first-line ACT suitable for both individual and community-level deployment.

 

Regulatory Recognition and WHO Prequalification

When you buy Pyramax tablets for Plasmodium falciparum treatment, you are choosing a medicine that has met the world’s most stringent regulatory standards:

• European Medicines Agency (EMA) positive scientific opinion granted under Article 58, making Pyramax the first ACT to achieve this distinction
• WHO List of Prequalified Medicinal Products — tablets (2012) and granules (2016)
• WHO Model List of Essential Medicines — included in 2017
• Registered in over 25 malaria-endemic countries including numerous nations across sub-Saharan Africa and Southeast Asia

This level of recognition reflects the consistent quality, safety, and efficacy data that Shin Poong Pharmaceutical and MMV have accumulated over more than two decades of dedicated research.

 

Safety Profile and Tolerability

Pyramax tablets have a well-characterised safety profile established across thousands of patients in both controlled clinical trials and real-world settings. The most commonly observed effects are transient and manageable:

• Transient ALT elevations (liver enzyme increases), typically peaking between Days 3–7 and normalising by Day 28
• Mild haemoglobin reductions of up to 2 g/dL, consistent with other antimalarial therapies
• Generally well-tolerated across a broad range of patient populations, including children

Pyramax is available on prescription only. Patients with pre-existing liver conditions or those taking other hepatotoxic medicines should be monitored appropriately. Consult your healthcare provider before commencing treatment.

 

Buy Pyramax Tablets at Faaiz Pharmacy

Faaiz Pharmacy is committed to making quality-assured, prescription antimalarials accessible to patients and healthcare providers across our service areas. When you buy Pyramax tablets for Plasmodium falciparum treatment through Faaiz Pharmacy, you benefit from:

• Authentic, manufacturer-sourced stock from Shin Poong Pharmaceutical Co. Ltd.
• Knowledgeable pharmacy support to answer dosing and product queries
• Reliable dispensing with full prescription compliance
• Competitive pricing on a WHO-essential antimalarial

 

Frequently Asked Questions

Can Pyramax treat both falciparum and vivax malaria? Yes. Pyramax tablets are uniquely approved for the treatment of both Plasmodium falciparum and Plasmodium vivax malaria — the only ACT to hold this dual indication.

How long is the Pyramax treatment course? Pyramax 180 mg/60 mg tablet dosage is one dose per day for three consecutive days, with the number of tablets per dose determined by the patient’s weight.

Is Pyramax suitable for children? Pyramax tablets are suitable for children weighing 20 kg or more. For children between 5 kg and 20 kg, Pyramax granules for oral suspension are the appropriate formulation.

Is a prescription required? Yes. Pyramax is a prescription-only medicine. Always consult a qualified healthcare professional before use.

 

* Pyramax® is a registered trademark of Shin Poong Pharmaceutical Co. Ltd. This product page is for informational purposes only and does not constitute medical advice. Always follow the guidance of a licensed healthcare professional.